ClinicalTrials.gg
CompletedNCT02250443BYM338Updated Dec 30, 2020Results posted

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

A Phase 2/3 interventional study of BYM338 (Bimagrumab) in Sporadic Inclusion Body Myositis (sIBM), sponsored by Novartis Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-12-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Myositis, Inclusion Body with a site in United States — 4 open to participants now, 9 under way, 2 of them phase 3. Myositis, Inclusion Body · United States.

Enrollment
23rd of 27
10 · median 24
Started
2014
with 1 other
Phase 2/3
6 of 37
none open now
Registered
19th of 37
by date
Lead sponsor
6 of 37
Novartis Pharmaceuticals

Among the 37 studies in Myositis, Inclusion Body with a site in United States, this one is the 23rd largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2014, is one of 6 in phase 2/3, and was the 19th registered.

Myositis, Inclusion Body

65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.

Browse Myositis, Inclusion Body studies →

Open to participants now

4 of the 37 studies in Myositis, Inclusion Body with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Myositis, Inclusion Body studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Myositis, Inclusion Body with a site in United States, or all of them as a file.
02

Study summary

This study is an open-label, long-term study for those patients who participated in the prior proof-of-concept protocol, in which the preliminary efficacy for BYM338 in patients with sIBM was demonstrated after a single 30 mg/kg i.v. dose of BYM338. This study is designed to confirm the efficacy, safety and tolerability of BYM338 in sIBM with long-term dosing. However due to lack of efficacy in patients with sIBM, the study was terminated early.

Read the detailed description

This is a non-confirmatory, multicenter, open-label, non-randomized trial which will extend active treatment to those patients that participated in the preceding proof-of-concept study (CBYM338X2205) in order to collect long-term safety and tolerability data. Up to 14 patients with sIBM will be invited to enroll into the study to receive BYM338 open-label for a period of approximately 3 years or until BYM338 is commercially available, whichever comes first. The study consists of a maximum 28-day screening period, a 5-day baseline period, and a treatment period consisting of the site visits at 4-week intervals for treatment administration, safety and pharmacokinetic follow-up. All patients will be administered a medium level i.v. BYM338 dose regardless of their treatment allocation in the prior study.

03

Conditions studied

  • Sporadic Inclusion Body Myositis (sIBM)

Keywords

  • Inclusion Body Myositis (IBM)
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed.
  • Patients who participated in the CBYM338X2205 study. A patient is defined as participating in the study if they were enrolled and received study medication.
  • Able to communicate well with the investigator, to understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Patients for whom the treating physician considers it inappropriate for continuation into the study, including consideration of physical and laboratory assessment of the patient at screening.
  • Patients who were non-compliant or demonstrated a serious protocol deviation in the previous study.
  • Use of other drugs at the time of enrollment, within 30 days or 5 half-lives of enrollment, or until the expected PD effect has returned to baseline, whichever is longer; or longer if required by local regulations.
  • History of to any of the study drugs or to drugs of similar chemical classes
  • Swallowing difficulty or other reason that precludes adequate intake of energy and protein, defined as at least 20 kcal/kg/day and 0.6 g protein/kg/day as determined by the investigators assessment.
  • On the Columbia-Suicide Severity Rating Scale, a score of 4 or 5 on the Suicidal Ideation item or any "yes" on the Suicidal Behavior item that is related to suicidal behavior occurring during the last 2 years.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  • Women of , defined as all women physiologically capable of becoming pregnant, must use highly effective during the study and for 5 half-lives (14 weeks) after stopping treatment. Highly effective contraception is defined as either:

    1. Total abstinence: When this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception].
    2. Sterilization: have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    3. Male partner sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). [For female study subjects, the vasectomized male partner should be the sole partner for that patient].
    4. Use of a combination of any two of the following (a+b or a+c or b+c):

    <!-- -->

    1. Use of oral, injected or implanted hormonal methods of contraception.
    2. Placement of an intrauterine device (IUD) or intrauterine system (IUS).
    3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.

In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. females must have had no regular menstrual bleeding for at least one (1) year prior to initial dosing. Menopause will be confirmed by a plasma FSH level of > 40 IU/L (or as determined by the cut off used by the local clinical laboratory) at screening. Female patients who report surgical sterilization must have had the procedure at least six (6) months prior to initial dosing. Surgical sterilization procedures should be supported with clinical documentation made available to the sponsor and noted in the Relevant Medical History / Current Medical Conditions section of the eCRF. All female patients must have negative pregnancy test results at screening and baseline.

  • Use of oral beta agonists, oral , androgens or androgen inhibitors (including LHRH agonists), or intravenous gamma globulin (IVIG) within the previous 6 months. Short-term corticosteroids for unrelated indications, defined as \< 20 mg/d for \< 30 days and ending at least 60 days prior to screening, are acceptable.
  • Patients with known bleeding disorders, or who are under treatment with anti-coagulants.
  • A presence or history of abnormalities, or including but not limited to Long syndrome, ischemic changes that cannot be shown to be stable for at least 6 months by previous ECG, or 2nd degree Mobitz II or 3rd degree heart block.
  • History of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  • Significant illness which has not resolved within two (2) weeks prior to initial dosing.
  • A positive , surface antigen or test result. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    BYM338

    BYM338 Group

    Drug: BYM338 (Bimagrumab)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    Any Adverse Event was defined as occurrence of any symptom regardless of intensity grade, Serious Adverse Event (SAEs) assessed as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in persistent or significant disability/incapacity

    Time frame: Up to 29 month

Secondary outcomes

  1. Changes From Baseline in Lean Body Mass (LBM) by Dual-Energy X-ray Absorptiometery (DXA)

    To assess the effect of multiple doses of BYM338 on lean body mass as measured by DXA in terms of change from baseline.

    Time frame: Baseline, Day 1, 57, 113, 169, 365, 533, and day 729

  2. Pharmacokinetics (PK) Parameter of Cmin From Multiple i.v. Dosing

    To obtain pharmacokinetic data from multiple i.v. dosing of BYM338 in this patient population. Pre-dose, 30 mins \& 4 hours post-dose on Day 1. Pre-dose only on each subsequent administration

    Time frame: Day 29, 85, 169, 253, 337, 421, 505, 589, 673, 757, 1177

  3. Changes From Baseline in Physical Function Reported by Patients

    Self-reported physical function was assessed by a newly developed patient reported outcome named sporadic inclusion body myositis (sIBM) functional assessment (sIFA). The sIFA consists of 11 items scored on an 11 point numerical rating scale from 0 (no difficulty) to 10 (unable to do) across 3 domains: upper body functioning, lower body functioning and general functioning. Participants completed the assessment where the recall period was the past week prior to completing the patient reported outcome (PRO). The total score on the sIFA scale ranges from 0 (minimum) to 110 (maximum). Higher values represent a worse outcome. A positive change from baseline indicates deterioration. Due to the no-signal this analysis was cancelled.

    Time frame: Baseline, Week 104

  4. Changes From Baseline in Muscle Strength.

    Quadriceps muscle strength was measured, Quadriceps Quantitative Muscle Testing (QMT) by portable fixed dynamometry (PFD). A negative change from baseline indicates deterioration

    Time frame: Baseline, Day 1, 113, 169, 365, 533, 729

  5. Changes From Baseline in Muscle Function (Hand-grip and Pinch-grip Dynamometry)

    The effect of BYM338 on additional muscle function measures (hand-grip and pinch-grip dynamometry).

    Time frame: Baseline,Day 1, 113, 169, 365, 533, 729

  6. Changes From Baseline in Muscle Function 6 Minute Walking Distance

    The effect of BYM338 on additional muscle function measures (6 minute walking distance). The 6MWD test measured the distance (in meters) that a participant walked in a 6 minute timeframe. A positive change from baseline indicates improvement.

    Time frame: Baseline,Day 1, 113, 169, 365, 533, 729

  7. Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan

    Thigh Muscle Volume (TMV) change was evaluated by a responder analysis. Patients whose loss of muscle TMV by MRI was equal or more than 2% at Week 8 and 16 were considered responders

    Time frame: Baseline, Day 1, 57, 113

  8. Pharmacokinetics (PK) Parameter of Cmax

    To obtain pharmacokinetic data from multiple i.v. dosing of BYM338 in this patient population. Pre-dose, 30 mins \& 4 hours post-dose on Day 1.

    Time frame: Day 1

  9. Time to Reach the Maximum Concentration After Drug Administration (Tmax)

    The time to reach the maximum concentration after drug administration

    Time frame: Day 1

07

Results

Posted Apr 10, 2018

Participant flow

Due to lack of efficacy in patients with sIBM, the study was terminated early.

Participant flow — Overall Study
MilestoneBYM338
Started10
Completed0
Not completed10
Withdrew: Administrative problems7
Withdrew: Adverse event3

Outcome measures

PrimaryNumber of Participants With Adverse Events as a Measure of Safety and Tolerability

Any Adverse Event was defined as occurrence of any symptom regardless of intensity grade, Serious Adverse Event (SAEs) assessed as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in persistent or significant disability/incapacity

Time frame:
Up to 29 month
Reported as:
Number · Participants
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
ParticipantsBYM338
Death0
Serious adverse events (SAE)2
Adverse Events (AE)10
SecondaryChanges From Baseline in Lean Body Mass (LBM) by Dual-Energy X-ray Absorptiometery (DXA)

To assess the effect of multiple doses of BYM338 on lean body mass as measured by DXA in terms of change from baseline.

Time frame:
Baseline, Day 1, 57, 113, 169, 365, 533, and day 729
Reported as:
Mean · Percentage Change in LBM
Changes From Baseline in Lean Body Mass (LBM) by Dual-Energy X-ray Absorptiometery (DXA)
Percentage Change in LBMBYM338
Day 10 ± 0
Day 574.292 ± 2.7480
Day 1135.552 ± 3.6066
Day 1697.463 ± 4.5687
Day 3656.919 ± 2.9669
Day 5336.885 ± 3.7894
Day 7290.727 ± NA
SecondaryPharmacokinetics (PK) Parameter of Cmin From Multiple i.v. Dosing

To obtain pharmacokinetic data from multiple i.v. dosing of BYM338 in this patient population. Pre-dose, 30 mins \& 4 hours post-dose on Day 1. Pre-dose only on each subsequent administration

Time frame:
Day 29, 85, 169, 253, 337, 421, 505, 589, 673, 757, 1177
Reported as:
Mean · ng/mL
Pharmacokinetics (PK) Parameter of Cmin From Multiple i.v. Dosing
ng/mLBYM338
Day 29 (n=10)13.4 ± 5.01
Day 85 (n=10)24.1 ± 13.1
Day 169 (n=10)26.3 ± 15.9
Day 253 (n=9)28.8 ± 12.1
Day 337 (n=10)24.4 ± 14.6
Day 421 (n=9)24.5 ± 11.5
Day 505 (n=8)28.3 ± 10.6
Day 589 (n=6)39.8 ± 30.2
Day 673 (n=2)20.5 ± 1.98
Day 757 (n=1)20.3 ± NA
Day 1177 (n=1)31.4 ± NA
SecondaryChanges From Baseline in Physical Function Reported by Patients

Self-reported physical function was assessed by a newly developed patient reported outcome named sporadic inclusion body myositis (sIBM) functional assessment (sIFA). The sIFA consists of 11 items scored on an 11 point numerical rating scale from 0 (no difficulty) to 10 (unable to do) across 3 domains: upper body functioning, lower body functioning and general functioning. Participants completed the assessment where the recall period was the past week prior to completing the patient reported outcome (PRO). The total score on the sIFA scale ranges from 0 (minimum) to 110 (maximum). Higher values represent a worse outcome. A positive change from baseline indicates deterioration. Due to the no-signal this analysis was cancelled.

Time frame:
Baseline, Week 104

No measurements were reported for this outcome.

SecondaryChanges From Baseline in Muscle Strength.

Quadriceps muscle strength was measured, Quadriceps Quantitative Muscle Testing (QMT) by portable fixed dynamometry (PFD). A negative change from baseline indicates deterioration

Time frame:
Baseline, Day 1, 113, 169, 365, 533, 729
Reported as:
Mean · Newtons
Changes From Baseline in Muscle Strength.
NewtonsBYM338
Quadriceps score left side Day 10 ± 0
left side Day 113-5.80 ± 28.160
left side Day 169-5.95 ± 26.587
left side Day 365-9.51 ± 28.149
left side Day 533-25.77 ± 21.321
left side Day 729178.26 ± NA
Quadriceps score Right side Day 10 ± 0
Right side Day 113-4.83 ± 29.904
Right side Day 169-22.81 ± 18.784
Right side Day 365-11.63 ± 47.141
Right side Day 533-31.00 ± 29.173
Right side Day 729-57.66 ± NA
SecondaryChanges From Baseline in Muscle Function (Hand-grip and Pinch-grip Dynamometry)

The effect of BYM338 on additional muscle function measures (hand-grip and pinch-grip dynamometry).

Time frame:
Baseline,Day 1, 113, 169, 365, 533, 729
Reported as:
Mean · Newtons
Changes From Baseline in Muscle Function (Hand-grip and Pinch-grip Dynamometry)
NewtonsBYM338
Left hand-grip day 10 ± 0
Left hand-grip day 11325.58 ± 37.544
Left hand-grip day 16921.36 ± 43.815
Left hand-grip day 365-1.42 ± 47.973
Left hand-grip day 5332.78 ± 16.934
Left hand-grip day 7298.95 ± 24.034
Right hand-grip day 10 ± 0
Right hand-grip day 11399.59 ± 184.472
Right hand-grip day 169109.05 ± 214.248
Right hand-grip day 36577.46 ± 160.133
Right hand-grip day 53353.99 ± 127.776
Right hand-grip day 729163.66 ± 237.402
Left hand pinch grip day 10 ± 0
Left hand pinch grip day 1137.82 ± 27.292
Left hand pinch grip day 169-4.74 ± 20.210
Left hand pinch grip day 365-7.30 ± 35.224
Left hand pinch grip day 533-11.40 ± 21.204
Left hand pinch grip day 729-8.41 ± 46.672
Right hand pinch grip day 10 ± 0
Right hand pinch grip day 113-7.55 ± 26.792
Right hand pinch grip day 169-9.35 ± 30.942
Right hand pinch grip day 3650.59 ± 32.094
Right hand pinch grip day 533-8.65 ± 21.491
Right hand pinch grip day 729-35.40 ± 44.820
SecondaryChanges From Baseline in Muscle Function 6 Minute Walking Distance

The effect of BYM338 on additional muscle function measures (6 minute walking distance). The 6MWD test measured the distance (in meters) that a participant walked in a 6 minute timeframe. A positive change from baseline indicates improvement.

Time frame:
Baseline,Day 1, 113, 169, 365, 533, 729
Reported as:
Mean · Meters
Changes From Baseline in Muscle Function 6 Minute Walking Distance
MetersBYM338
Day 10 ± 0
Day 113-1.56 ± 13.685
Day 169-7.41 ± 12.463
Day 365-8.97 ± 15.763
Day 533-16.99 ± 22.382
Day 729-17.86 ± NA
SecondaryChange From Baseline of Thigh Muscle Volume (TMV) by MRI Scan

Thigh Muscle Volume (TMV) change was evaluated by a responder analysis. Patients whose loss of muscle TMV by MRI was equal or more than 2% at Week 8 and 16 were considered responders

Time frame:
Baseline, Day 1, 57, 113
Reported as:
Mean · Percentage Change
Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan
Percentage ChangeBYM338
Day 10 ± 0
Day 574.14 ± 4.250
Day 1134.51 ± 6.300
SecondaryPharmacokinetics (PK) Parameter of Cmax

To obtain pharmacokinetic data from multiple i.v. dosing of BYM338 in this patient population. Pre-dose, 30 mins \& 4 hours post-dose on Day 1.

Time frame:
Day 1
Reported as:
Mean · ug/mL
Pharmacokinetics (PK) Parameter of Cmax
ug/mLBYM338
Pharmacokinetics (PK) Parameter of Cmax278 ± 62.6
SecondaryTime to Reach the Maximum Concentration After Drug Administration (Tmax)

The time to reach the maximum concentration after drug administration

Time frame:
Day 1
Reported as:
Median · hr
Time to Reach the Maximum Concentration After Drug Administration (Tmax)
hrBYM338
Time to Reach the Maximum Concentration After Drug Administration (Tmax)0.744 ± NA

Adverse events

Collected over period up to 104 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BYM338 10mg/kg i.v.—2/10 (20%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventBYM338 10mg/kg i.v.
AnaemiaBlood and lymphatic system disorders1/10
Myocardial infarctionCardiac disorders1/10
TachyarrhythmiaCardiac disorders1/10
Gastrointestinal haemorrhageGastrointestinal disorders1/10
Haemorrhoidal haemorrhageGastrointestinal disorders1/10
DehydrationMetabolism and nutrition disorders1/10
Iron deficiencyMetabolism and nutrition disorders1/10
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/10
Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/10
Most frequent other events
Showing 10 of 73
Most frequent other events
EventBYM338 10mg/kg i.v.
FallInjury, poisoning and procedural complications9/10
Muscle spasmsMusculoskeletal and connective tissue disorders9/10
DiarrhoeaGastrointestinal disorders6/10
Skin abrasionInjury, poisoning and procedural complications5/10
AcneSkin and subcutaneous tissue disorders5/10
Oedema peripheralGeneral disorders3/10
Urinary tract infectionInfections and infestations3/10
Ligament sprainInjury, poisoning and procedural complications3/10
ArthralgiaMusculoskeletal and connective tissue disorders3/10
RashSkin and subcutaneous tissue disorders3/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BYM338
Mean70.1 ± 10.39
Sex: Female, Male
Sex: Female, Male(Participants)BYM338
Female4
Male6
08

Study locations

2 sites
  • Novartis Investigative Site
    Phoenix, Arizona 85013, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02115, United States
09

References and documents

Publications

  • Sivakumar K, Cochrane TI, Sloth B, Ashar H, Laurent D, Tanko LB, Amato AA. Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis. Neurology. 2020 Oct 6;95(14):e1971-e1978. doi: 10.1212/WNL.0000000000010417. Epub 2020 Jul 20. PubMed 32690797 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Aug 2016, 29 months.

Results were first posted in Apr 2018, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2014
First posted
Sep 26, 2014
StartActual
Mar 11, 2014
Primary completionActual
Aug 23, 2016
CompletionActual
Aug 23, 2016
Results first posted
Apr 10, 2018
Last update
Dec 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02250443
Responsible party
Sponsor
First posted
Sep 26, 2014
Start date
Mar 11, 2014
Primary completion
Aug 23, 2016
Completion
Aug 23, 2016
Results posted
Apr 10, 2018
Last update
Dec 30, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimagrumab

Start the discussion